Compare EPR Properties (EPR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs IDEXX Laboratories, Inc. — how do they compare? EPR Properties trades at $62.12 (market cap $4.60B), while IDEXX Laboratories, Inc. trades at $574.92 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.6× EPR Properties's market cap, and EPR Properties pays a 6.19% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EPR | IDXX | |
|---|---|---|
Market Cap | $4.60B | $43.94B |
Sector | Real Estate | Health |
52-Week High | $60.81 | $766.68 |
52-Week Low | $48.71 | $514.61 |
Enterprise Value | $7.66B | $44.84B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $61.76, up 3.73% today, with a bullish technical signal from moving averages and recent breakout above key levels. The REIT shows strong profitability with 39.93% net income margin and consistent dividend payments, though Q1 2026 EPS slightly missed expectations. Recent news highlights monthly dividend declarations and a $315 million Six Flags acquisition diversifying its experiential portfolio.
Outlook remains positive with analyst consensus target of $63.25 offering modest upside, supported by 99% occupancy and stable cash flows. Risks include economic sensitivity of entertainment assets and potential interest rate impacts on REIT valuations. The stock presents a balance of income and growth for investors seeking REIT exposure.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
